Publications Update # 60 PARP inhibitors in ovarian cancer and recent withdrawals, Current FDA indications, Platinum resistant ovarian cancer management, SIENDO trial
CONCERV Trial Conservative surgery is feasible for select patients with early-stage, low-risk cervical cancer